OA11872A - Polymorph of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzyÜthiazolidine-2,4-dione, maleic acid salt. - Google Patents

Polymorph of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzyÜthiazolidine-2,4-dione, maleic acid salt. Download PDF

Info

Publication number
OA11872A
OA11872A OA1200100276A OA1200100276A OA11872A OA 11872 A OA11872 A OA 11872A OA 1200100276 A OA1200100276 A OA 1200100276A OA 1200100276 A OA1200100276 A OA 1200100276A OA 11872 A OA11872 A OA 11872A
Authority
OA
OAPI
Prior art keywords
polymorph
polymorph according
compound
provides
diabetes mellitus
Prior art date
Application number
OA1200100276A
Other languages
English (en)
French (fr)
Inventor
Paul David James Blackler
Christine Marie Browne
Timothy G Coakley
Robert Gordon Giles
Gillian Morrissey
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909473.2A external-priority patent/GB9909473D0/en
Priority claimed from GBGB9912196.4A external-priority patent/GB9912196D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Plc
Publication of OA11872A publication Critical patent/OA11872A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200100276A 1999-04-23 2000-04-19 Polymorph of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzyÜthiazolidine-2,4-dione, maleic acid salt. OA11872A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909473.2A GB9909473D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912196.4A GB9912196D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
OA11872A true OA11872A (en) 2006-03-27

Family

ID=26315461

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100276A OA11872A (en) 1999-04-23 2000-04-19 Polymorph of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzyÜthiazolidine-2,4-dione, maleic acid salt.

Country Status (40)

Country Link
US (2) US6806280B1 (ru)
EP (2) EP1173435B1 (ru)
JP (1) JP2002543077A (ru)
KR (1) KR100744360B1 (ru)
CN (1) CN1167702C (ru)
AP (1) AP1598A (ru)
AR (2) AR023561A1 (ru)
AT (1) ATE246191T1 (ru)
AU (1) AU765005B2 (ru)
BG (1) BG65485B1 (ru)
BR (1) BR0009932A (ru)
CA (1) CA2370280A1 (ru)
CO (1) CO5170421A1 (ru)
CZ (1) CZ20013800A3 (ru)
DE (1) DE60004196T2 (ru)
DK (1) DK1173435T3 (ru)
DZ (1) DZ3156A1 (ru)
EA (1) EA004541B1 (ru)
ES (1) ES2203453T3 (ru)
HK (1) HK1045153B (ru)
HR (1) HRP20010772B1 (ru)
HU (1) HUP0200931A3 (ru)
IL (1) IL146111A0 (ru)
MA (1) MA25356A1 (ru)
MX (1) MXPA01010821A (ru)
MY (1) MY131973A (ru)
NO (1) NO320574B1 (ru)
NZ (1) NZ515168A (ru)
OA (1) OA11872A (ru)
PE (1) PE20010044A1 (ru)
PL (1) PL351684A1 (ru)
PT (1) PT1173435E (ru)
SK (1) SK286427B6 (ru)
TR (1) TR200103062T2 (ru)
TW (1) TWI283677B (ru)
UA (1) UA67844C2 (ru)
UY (1) UY26121A1 (ru)
WO (1) WO2000064896A1 (ru)
YU (1) YU75301A (ru)
ZA (1) ZA200108719B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
AU765498B2 (en) 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
SK3752003A3 (sk) * 2000-09-26 2005-03-04 Dr. Reddy's Laboratories Limited Polymorfné formy 5-[4[2-[N-metyl-N-(2- pyridyl)aminol]etoxy]benzyl]tiazolidín-2,4-dión maleátu a spôsob ich prípravy
DE60216641T2 (de) * 2002-04-19 2007-09-27 Faes Farma S.A. Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US6462337B1 (en) * 2000-04-20 2002-10-08 Agilent Technologies, Inc. Mass spectrometer electrospray ionization
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
US6632947B2 (en) * 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US7091359B2 (en) * 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6613785B2 (en) * 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
UA67845C2 (ru) 1999-04-23 2004-07-15 Smithkline Beecham Plc Полиморф 5-[4-[2- (n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона соли малеиновой кислоты
AU765498B2 (en) * 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
SK3752003A3 (sk) 2000-09-26 2005-03-04 Dr. Reddy's Laboratories Limited Polymorfné formy 5-[4[2-[N-metyl-N-(2- pyridyl)aminol]etoxy]benzyl]tiazolidín-2,4-dión maleátu a spôsob ich prípravy

Also Published As

Publication number Publication date
HUP0200931A3 (en) 2004-03-29
HRP20010772A2 (en) 2002-10-31
AR023565A1 (es) 2002-09-04
PT1173435E (pt) 2003-12-31
AU4130800A (en) 2000-11-10
JP2002543077A (ja) 2002-12-17
NO20015147D0 (no) 2001-10-22
AR023561A1 (es) 2002-09-04
ATE246191T1 (de) 2003-08-15
CZ20013800A3 (cs) 2002-04-17
EP1304330A3 (en) 2003-11-19
ES2203453T3 (es) 2004-04-16
NO320574B1 (no) 2005-12-27
DZ3156A1 (fr) 2000-11-02
CO5170421A1 (es) 2002-06-27
DK1173435T3 (da) 2003-11-24
HRP20010772B1 (en) 2007-05-31
PE20010044A1 (es) 2001-03-10
WO2000064896A9 (en) 2001-10-25
MXPA01010821A (es) 2003-09-04
DE60004196D1 (de) 2003-09-04
HUP0200931A2 (en) 2002-08-28
AP1598A (en) 2006-04-26
WO2000064896A1 (en) 2000-11-02
CN1356999A (zh) 2002-07-03
MY131973A (en) 2007-09-28
AP2001002330A0 (en) 2000-12-31
HK1045153A1 (en) 2002-11-15
BG106121A (en) 2002-05-31
UA67844C2 (ru) 2004-07-15
PL351684A1 (en) 2003-06-02
EP1304330A2 (en) 2003-04-23
TWI283677B (en) 2007-07-11
CN1167702C (zh) 2004-09-22
AU765005B2 (en) 2003-09-04
ZA200108719B (en) 2002-06-21
SK286427B6 (sk) 2008-09-05
EA200101121A1 (ru) 2002-04-25
NO20015147L (no) 2001-12-17
IL146111A0 (en) 2002-07-25
KR100744360B1 (ko) 2007-07-30
SK14922001A3 (sk) 2002-02-05
TR200103062T2 (tr) 2002-05-21
US6806280B1 (en) 2004-10-19
EP1173435A1 (en) 2002-01-23
HK1045153B (zh) 2004-07-09
CA2370280A1 (en) 2000-11-02
US20050080114A1 (en) 2005-04-14
KR20010110797A (ko) 2001-12-13
BR0009932A (pt) 2002-04-09
BG65485B1 (bg) 2008-09-30
NZ515168A (en) 2004-02-27
DE60004196T2 (de) 2004-04-15
UY26121A1 (es) 2000-12-29
MA25356A1 (fr) 2001-12-31
YU75301A (sh) 2004-07-15
EP1173435B1 (en) 2003-07-30
EA004541B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
OA11872A (en) Polymorph of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino)ethoxyÜbenzyÜthiazolidine-2,4-dione, maleic acid salt.
US7368574B2 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US6815457B1 (en) Thiazolidinedione derivative and its use as antidiabetic
OA11873A (en) Novel pharmaceutical.
US7230109B2 (en) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
OA11866A (en) Novel pharmaceutical.
OA11867A (en) Novel pharmaceutical.
ZA200108722B (en) Thiazolidinedione derivative and its use as antidiabetic.